Literature DB >> 29321396

[Molecular and cellular mechanisms underlying the sterile inflammation after ischemic stroke].

Takashi Shichita1.   

Abstract

Inflammation is an essential step for the pathology of ischemic stroke, and is also an important therapeutic target for developing novel therapeutic methods which have a wide therapeutic time window. Since there is no pathogen in the brain, the inflammation will be triggered by some endogenous molecules which are called as danger associated molecular patterns (DAMPs). So far two important DAMPs, high mobility group box 1 (HMGB1) and peroxiredoxin (PRX), have been recently identified in the ischemic brain. HMGB1 exaggerates the disruption of blood brain barrier; on the other hand, PRX activates mononuclear phagocytes and induces the inflammatory cytokine production through the activation of Toll-like receptor 2 (TLR2) and TLR4. Various inflammatory molecules produced from infiltrating immune cells have been known to exacerbate the neurological deficits of ischemic stroke patients. Recently, it has been paid attention that the inflammation after tissue injury also induces tissue repair, while its mechanisms remain to be clarified. Novel therapeutic methods will be established by clarifying detailed molecular mechanisms underlying the induction of neural repair after cerebral post-ischemic inflammation.

Entities:  

Mesh:

Year:  2018        PMID: 29321396     DOI: 10.1254/fpj.151.9

Source DB:  PubMed          Journal:  Nihon Yakurigaku Zasshi        ISSN: 0015-5691


  2 in total

Review 1.  Recent advances in the development of nanomedicines for the treatment of ischemic stroke.

Authors:  Xing Tian; Taojian Fan; Wentian Zhao; Ghulam Abbas; Bo Han; Ke Zhang; Nan Li; Ning Liu; Weiyuan Liang; Hao Huang; Wen Chen; Bing Wang; Zhongjian Xie
Journal:  Bioact Mater       Date:  2021-02-20

2.  Salidroside inhibits NLRP3 inflammasome activation and apoptosis in microglia induced by cerebral ischemia/reperfusion injury by inhibiting the TLR4/NF-κB signaling pathway.

Authors:  Jie Liu; Wei Ma; Cheng-Hao Zang; Guo-Dong Wang; Si-Jia Zhang; Hong-Jie Wu; Ke-Wei Zhu; Xiang-Lin Xiang; Chun-Yan Li; Kuang-Pin Liu; Jian-Hui Guo; Li-Yan Li
Journal:  Ann Transl Med       Date:  2021-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.